Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise and diet may protect the brain during CAR-T cancer treatment

NCT ID NCT07173166

Symptom relief Sponsor: Instituto de Investigacion Sanitaria INCLIVA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tests whether a structured exercise program, with or without nutritional advice, can lower the risk and severity of neurotoxicity (brain-related side effects) caused by CAR-T cell therapy in adults with blood cancers. One hundred participants will be randomly assigned to exercise, exercise plus diet, or usual care. The goal is to find a non-drug way to improve recovery and reduce cognitive problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
structured physical activity program and nutritional recommendations
What this could lead to
If it works, this could offer a simple, drug-free way to reduce brain-related side effects from CAR-T therapy, improving recovery and quality of life.
What could go wrong
This is an early-stage trial with only 100 participants, so results may not apply to everyone. The interventions are supportive and may not prevent severe neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 338 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients, aged 18 to 80 years. * Diagnosed with a hematological condition. * Initiating antineoplastic treatment with CAR-T cell therapy. Exclusion Criteria: * Presence of language barriers or physical and/or cognitive impairments that hinder the understanding of the interventions or prevent proper completion of the assessment tools used in the study. * Pre-existing neurological or psychiatric comorbidities that may interfere with the evaluation of neurotoxic effects of the hematologic treatment. * Concomitant treatment with additional neurotoxic drugs not related to the study protocol. * History of abusive consumption of neurotoxic substances.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Motor Activity toxic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Clínico Universitario de Valencia

    RECRUITING

    Valencia, Valencia, 46010, Spain

  • Hospital Universitario y Politécnico La Fe

    RECRUITING

    Valencia, Valencia, 46026, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.